Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double Blind, Parallel Group Study to Evaluate a 1:1 Dose Conversion From EPREX to EPIAO in Term of Clinical Efficacy and Safety in Subjects With End-Stage Renal Disease on Haemodialysis

Next Previous
X
Search
Trial Profile

A Prospective, Randomized, Double Blind, Parallel Group Study to Evaluate a 1:1 Dose Conversion From EPREX to EPIAO in Term of Clinical Efficacy and Safety in Subjects With End-Stage Renal Disease on Haemodialysis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Recombinant erythropoietin (Primary) ; Epoetin alfa
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms BEAT_002
  • Sponsors Shenyang Sunshine Pharmaceutical

    • Most Recent Events

    • 25 Nov 2022 Primary endpoint has been met, (Mean absolute change in weekly epoetin dosage per kg body weight from baseline to 6 months), as per Results published in the Medicine
    • 25 Nov 2022 Primary endpoint has been met, (Mean absolute change in haemoglobin level from baseline to 6 months), as per Results published in the Medicine
    • 25 Nov 2022 Results published in the Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top